Clinical trials sponsored by Genentech, Inc.

Phase breakdown

Conditions studied

Recruiting trials led by Genentech, Inc.

• A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
  NCT05800665 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 26 locations
• A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
  NCT07567846 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 5 locations
• A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
  NCT07609719 · Phase: Phase 4 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 3 locations
• A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
  NCT05968326 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 89 locations
• A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
  NCT07100106 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 64 locations
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
  NCT06979336 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 106 locations
• A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease
  NCT06603246 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
  NCT07629583 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location

Common questions

How many trials is Genentech, Inc. recruiting for?

Genentech, Inc. is the lead sponsor of 8 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.